Jeffrey G. Black - Aug 9, 2021 Form 4 Insider Report for Apollo Endosurgery, Inc. (APEN)

Role: Chief Financial Officer
Signature: /s/ Brian Szymczak - Attorney-in-Fact
Stock symbol: APEN
Transactions as of: Aug 9, 2021
Transactions value $: $1,522,250
Form type: 4
Date filed: 8/11/2021, 08:25 PM
Previous filing: Aug 6, 2021
Next filing: Mar 1, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APEN	Common Stock	Purchase	$219K	+25K		$8.75	25K	Aug 11, 2021	Direct	F1
transaction	APEN	Common Stock	Award	$0	+120K	+480%	$0.00	145K	Aug 9, 2021	Direct	F2
transaction	APEN	Common Stock	Award	$0	+80K	+55.17%	$0.00	225K	Aug 9, 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APEN	Stock Option (Right to Buy)	Award	$1.3M	+150K		$8.69	150K	Aug 9, 2021	Common Stock	150K	$8.69	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents weighted average price of shares purchased. Prices ranged between $8.40 - $9.00, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote.
F2	Represents the grant of Restricted Stock Units ("RSU"). Each RSU provides the Reporting Person with a contingent right to receive one share of the Issuer's common stock. One third of the RSU grant will vest upon the achievement of revenue for the trailing four quarters equal to each of $70 million, $90 million and $110 million, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan. The RSU grant will be governed by the terms of the 2017 Equity Incentive Plan.
F3	Represents the grant of RSUs. Each RSU provides the Reporting Person with a contingent right to receive one share of the Issuer's common stock. One quarter of the RSU grant will vest on the first anniversary of the effective date (August 3, 2021) and the remainder will vest in equal annual installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan. The RSU grant will be governed by the terms of the 2017 Equity Incentive Plan.
F4	The shares underlying the option shall vest as to 25% on the first anniversary of the effective date (August 3, 2021) and the remainder will vest in equal monthly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan.